Table 1.

Transmissible disease testing performed at Canadian Blood Services

Transmissible disease	Assay(s)	Sensitivity	Implementation year
HIV	Serological: •anti-HIV 1 and 2 NAT •HIV-1 M RNA •HIV-1 O RNA •HIV-2 RNA	•100% (99.56%-100%) •50.3 IU/mL§ •18.3 copies/mL§ •57.4 copies/mL§	1985 2001
HBV	Serological: •HBsAg •anti-HBc NAT •HBV DNA	•0.08-0.10 ng/mL •99.49% (98.82%-99.83%) •2.3 IU/mL§	1972 2005 2011
HCV	Serological •anti-HCV NAT •HCV RNA	•100% (99.49%-100%) •6.8 IU/mL§	1990 1999
HTLV I/II	Serological •anti-HTLV I/II	100% (99.48%-100%)	1990 (HTLV I); 1998 (HTLV I/II)
WNV	NAT •WNV RNA	40.3 copies/mL§	2003 (Seasonal, 2015)
Syphilis	Serological	100% (0.555-0.97)	1949
CMV⁎	Serological	99.4% (99.4%-100%)	1984
Chagas⁎	Serological	98.47% (94.59-99.81%)	2010

anti-HIV 1 and 2, antibodies to HIV-1 groups M and O and antibodies to HIV-2; NAT, nucleic acid testing; anti-HBc, total antibodies to hepatitis B core antigen; anti-HCV, antibodies to hepatitis C virus; anti-HTLV I/II, antibodies to human T-lymphotropic virus I and human T-lymphotropic virus type II.

^⁎Only selected units are tested.

^§Single unit limit of detection; theoretical sensitivity is calculated by multiplying single unit limit of detection by 6.